Edap Tms (NASDAQ:EDAP) Given New $10.00 Price Target at HC Wainwright

Key Points

• HC Wainwright cut its price target on Edap Tms from $14 to $10 but retained a "buy" rating, implying a potential upside of about 201.20% from the current share price.
• Analyst coverage is mixed — one Buy, two Hold and one Sell — and the consensus rating is a Hold with an average target of $6.00.
• The company missed EPS (reported -$0.25 vs. -$0.16 expected), showed negative margins and ROE, posted $22.22M in revenue, has a market cap of roughly $124M, and its shares trade around $3.32 with about 62.7% institutional ownership.

Edap Tms (NASDAQ:EDAP - Get Free Report) had its target price reduced by equities research analysts at HC Wainwright from $14.00 to $10.00 in a research note issued on Thursday,Benzinga reports. The firm presently has a "buy" rating on the medical equipment provider's stock. HC Wainwright's price target would suggest a potential upside of 201.20% from the company's current price.

A number of other research analysts have also commented on EDAP. Weiss Ratings reiterated a "sell (d-)" rating on shares of Edap Tms in a research note on Monday, December 29th. Wall Street Zen lowered shares of Edap Tms from a "hold" rating to a "sell" rating in a research note on Saturday, March 28th. One analyst has rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, Edap Tms has an average rating of "Hold" and a consensus target price of $6.00.

Edap Tms Price Performance

Shares of NASDAQ EDAP traded down $0.05 during mid-day trading on Thursday, reaching $3.32. 4,680 shares of the company traded hands, compared to its average volume of 64,757. Edap Tms has a fifty-two week low of $1.21 and a fifty-two week high of $5.05. The company has a debt-to-equity ratio of 0.84, a current ratio of 1.54 and a quick ratio of 1.19. The firm has a market cap of $124.13 million, a PE ratio of -4.31 and a beta of -0.09. The stock has a fifty day simple moving average of $4.14 and a 200-day simple moving average of $3.22.

Edap Tms (NASDAQ:EDAP - Get Free Report) last posted its quarterly earnings data on Wednesday, March 25th. The medical equipment provider reported ($0.25) EPS for the quarter, missing analysts' consensus estimates of ($0.16) by ($0.09). Edap Tms had a negative net margin of 41.24% and a negative return on equity of 100.07%. The company had revenue of $22.22 million for the quarter, compared to analyst estimates of $21.28 million. Equities research analysts anticipate that Edap Tms will post -0.6 EPS for the current fiscal year.

Institutional Trading of Edap Tms

Large investors have recently added to or reduced their stakes in the business. Financial Planning Navigators CORP bought a new stake in Edap Tms during the fourth quarter worth approximately $33,000. Kovack Advisors Inc. acquired a new position in Edap Tms in the 4th quarter worth approximately $53,000. Leonteq Securities AG acquired a new position in Edap Tms in the 4th quarter worth approximately $313,000. Flax Pond Capital LLC acquired a new position in Edap Tms in the 4th quarter worth approximately $2,623,000. Finally, Rock Springs Capital Management LP boosted its stake in Edap Tms by 1.3% in the 4th quarter. Rock Springs Capital Management LP now owns 1,286,500 shares of the medical equipment provider's stock worth $4,233,000 after purchasing an additional 16,500 shares during the period. 62.74% of the stock is currently owned by institutional investors.

About Edap Tms

Edap Tms SA NASDAQ: EDAP is a Lyon, France–based medical device company that develops and markets noninvasive therapeutic systems for urological applications. The firm's core focus lies in high-intensity focused ultrasound (HIFU) for localized prostate tissue ablation and extracorporeal shock-wave lithotripsy for kidney stone fragmentation. Edap Tms's Ablatherm HIFU platform delivers targeted ultrasound energy to treat prostate cancer without incisions, while its Sonolith line offers pulse-focused shock waves designed to break down urinary calculi.

Since its founding in 1989, Edap Tms has pursued regulatory clearances in multiple markets, including CE marking in Europe and FDA clearance for its HIFU system in the United States.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.